Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2004 2
2005 3
2006 2
2007 2
2008 3
2009 2
2010 4
2011 7
2012 8
2013 5
2014 8
2015 5
2016 5
2017 9
2018 11
2019 3
2020 4
2021 4
2022 2
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Study on the Complex Melanoma.
Fateeva A, Chen S. Fateeva A, et al. Among authors: chen s. Cancers (Basel). 2024 Feb 20;16(5):843. doi: 10.3390/cancers16050843. Cancers (Basel). 2024. PMID: 38473205 Free PMC article.
Assessing Longitudinal Treatment Efficacies and Alterations in Molecular Markers Associated with Glutamatergic Signaling and Immune Checkpoint Inhibitors in a Spontaneous Melanoma Mouse Model.
Eddy K, Gupta K, Eddin MN, Marinaro C, Putta S, Sauer JM Jr, Chaly A, Freeman KB, Pelletier JC, Fateeva A, Furmanski P, Silk AW, Reitz AB, Zloza A, Chen S. Eddy K, et al. Among authors: chen s. JID Innov. 2024 Jan 18;4(2):100262. doi: 10.1016/j.xjidi.2024.100262. eCollection 2024 Mar. JID Innov. 2024. PMID: 38445232 Free PMC article.
Overview of current melanoma therapies.
Fateeva A, Eddy K, Chen S. Fateeva A, et al. Among authors: chen s. Pigment Cell Melanoma Res. 2023 Dec 8. doi: 10.1111/pcmr.13154. Online ahead of print. Pigment Cell Melanoma Res. 2023. PMID: 38063139 Review.
Editorial: The role of immunotherapy in melanomas.
Fateeva A, Chen S. Fateeva A, et al. Among authors: chen s. Front Oncol. 2023 Sep 28;13:1293040. doi: 10.3389/fonc.2023.1293040. eCollection 2023. Front Oncol. 2023. PMID: 37841439 Free PMC article. No abstract available.
A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850.
Spencer KR, Portal DE, Aisner J, Stein MN, Malhotra J, Shih W, Chan N, Silk AW, Ganesan S, Goodin S, Gounder M, Lin H, Li J, Cerchio R, Marinaro C, Chen S, Mehnert JM. Spencer KR, et al. Among authors: chen s. Oncotarget. 2023 Apr 10;14:302-315. doi: 10.18632/oncotarget.28403. Oncotarget. 2023. PMID: 37036756 Free PMC article. Clinical Trial.
A Spontaneous Melanoma Mouse Model Applicable for a Longitudinal Chemotherapy and Immunotherapy Study.
Eddy K, Gupta K, Pelletier JC, Isola AL, Marinaro C, Rasheed MA, Campagnolo J, Eddin MN, Rossi M, Fateeva A, Reuhl K, Shah R, Robinson AK, Chaly A, Freeman KB, Chen W, Diaz J, Furmanski P, Silk AW, Reitz AB, Zloza A, Chen S. Eddy K, et al. Among authors: chen s. J Invest Dermatol. 2023 Oct;143(10):2007-2018.e6. doi: 10.1016/j.jid.2023.03.1664. Epub 2023 Mar 29. J Invest Dermatol. 2023. PMID: 36997110 Free article.
A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors.
Silk AW, Saraiya B, Groisberg R, Chan N, Spencer K, Girda E, Shih W, Palmeri M, Saunders T, Berman RM, Coric V, Chen S, Zloza A, Vieth J, Mehnert JM, Malhotra J. Silk AW, et al. Among authors: chen s. Eur J Med Res. 2022 Jul 2;27(1):107. doi: 10.1186/s40001-022-00732-w. Eur J Med Res. 2022. PMID: 35780243 Free PMC article. Clinical Trial.
91 results